MedTrace Logo

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

NCT05732051 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-03-17

No results posted yet for this study

Summary

Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy

DIETARY_SUPPLEMENT

Placebo

Matching placebo b.i.d as long as the patient is receiving anthracycline therapy

Sponsors & Collaborators

  • ChromaDex, Inc.

    collaborator INDUSTRY

  • Norwegian Cancer Society

    collaborator OTHER

  • Norwegian Breast Cancer Association

    collaborator UNKNOWN

  • Helse Sor-Ost

    collaborator OTHER_GOV

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Torbjørn Omland, MD, PhD · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-16
Primary Completion
2025-08-01
Completion
2035-09-30
FDA Drug
Yes

Countries

  • Norway

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05732051 on ClinicalTrials.gov